A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Korábbi kezelés

• History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.
• They will not have had a myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months prior to first dose of study treatment.

Más betegség

• Participants can have no history of other malignancy in the last 2 years.
• Any symptomatic central nervous system (CNS) metastases, or leptomeningeal disease.
• They will have no history of severe or life-threatening events to immune-mediated therapy.
• They will have no active autoimmune or inflammatory disorders.
• Presence of active human immunodeficiency virus (HIV) or active Hepatitis (B/C) infection.
• Evidence or interstitial lung disease (ILD) or active, non-infectious pneumonitis.
• History of solid organ transplant.

• Participant has provided informed consent before initiation of any study-specific activities/procedures.
• Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.
• Histologically or cytologically documented ES-SCLC (American Joint Committee on Cancer, 2017, Stage IV SCLC \[T any, N any, M1 a/b/c\]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.
• Measurable disease as defined per RECIST 1.1.
• Suitable to receive carboplatin, etoposide and durvalumab regimen as first-line treatment per investigator clinical assessment.
• Minimum life expectancy ≥ 12 weeks.